What Clinicians Should Know About Kratom and 7-OH Mitragynine: Treatment Guidance and Regulatory Status

Why it matters

Leading clinical journal publishes guidance for physicians on recognizing and treating kratom use disorder and 7-OH dependence. Given widespread patient use for self-management of opioid withdrawal and recreational purposes, clinician education is critical as cases mount in emergency departments.

The big picture

Kratom and 7-OH products are sold in smoke shops, gas stations, and online with minimal regulation and no FDA approval. 7-OH has up to 22 times greater affinity than morphine for mu opioid receptors. Patients use kratom for wellness, energy, pain management, mood, and to self-manage opioid dependence. No evidence-based medical indication exists for either compound. FDA recommended 7-OH classification as Schedule I in July 2025.

Key findings

• 7-OH has 22 times greater mu-receptor affinity than morphine
• Neither kratom nor derivatives appear on standard toxicology tests
• Newer products like 7-OH gummies and drinks enable high-dose consumption without awareness
• Reported complications include seizures, aphasia, cardiac arrest, hepatic/renal injury, overdose, and death
• Buprenorphine is preferred treatment for kratom dependence

What they say

Clinical review: "There are risks for having a widely available and minimally regulated substance that can cause dependence and use disorder...To date, the risks for kratom and 7-OH use are poorly understood by physicians and the public alike." Authors recommend buprenorphine as best practice for kratom/7-OH dependence treatment.

Bottom line

**Clinicians should recognize kratom and 7-OH dependence as a distinct use disorder requiring buprenorphine treatment similar to opioid use disorder, while advocating for point-of-sale education and market regulation.**